nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—Atenolol—Procarbazine—hematologic cancer	0.267	1	CrCrCtD
Metoprolol—ABCB1—hematologic cancer	0.0961	1	CbGaD
Metoprolol—SLC22A2—Daunorubicin—hematologic cancer	0.0365	0.0882	CbGbCtD
Metoprolol—SLC22A2—Cytarabine—hematologic cancer	0.0322	0.0778	CbGbCtD
Metoprolol—SLC22A2—Cladribine—hematologic cancer	0.0304	0.0734	CbGbCtD
Metoprolol—SLC22A2—Imatinib—hematologic cancer	0.0279	0.0675	CbGbCtD
Metoprolol—ABCB1—Lenalidomide—hematologic cancer	0.0166	0.04	CbGbCtD
Metoprolol—SLC22A2—Vinblastine—hematologic cancer	0.0155	0.0375	CbGbCtD
Metoprolol—CYP2D6—Lomustine—hematologic cancer	0.0145	0.0351	CbGbCtD
Metoprolol—SLC22A2—Cisplatin—hematologic cancer	0.0142	0.0344	CbGbCtD
Metoprolol—CYP2D6—Idarubicin—hematologic cancer	0.0129	0.0313	CbGbCtD
Metoprolol—CYP2C19—Bortezomib—hematologic cancer	0.0126	0.0304	CbGbCtD
Metoprolol—CYP2D6—Hydroxyurea—hematologic cancer	0.011	0.0266	CbGbCtD
Metoprolol—CYP2C19—Thalidomide—hematologic cancer	0.011	0.0265	CbGbCtD
Metoprolol—CYP2C19—Teniposide—hematologic cancer	0.0105	0.0253	CbGbCtD
Metoprolol—ABCB1—Daunorubicin—hematologic cancer	0.00971	0.0235	CbGbCtD
Metoprolol—CYP2C19—Ifosfamide—hematologic cancer	0.00965	0.0233	CbGbCtD
Metoprolol—CYP2D6—Bortezomib—hematologic cancer	0.00956	0.0231	CbGbCtD
Metoprolol—ABCB1—Alitretinoin—hematologic cancer	0.00951	0.023	CbGbCtD
Metoprolol—CYP2C19—Imatinib—hematologic cancer	0.00922	0.0223	CbGbCtD
Metoprolol—ABCB1—Imatinib—hematologic cancer	0.00744	0.018	CbGbCtD
Metoprolol—CYP2D6—Imatinib—hematologic cancer	0.00701	0.0169	CbGbCtD
Metoprolol—ABCB1—Nilotinib—hematologic cancer	0.00676	0.0163	CbGbCtD
Metoprolol—ABCB1—Vinorelbine—hematologic cancer	0.0067	0.0162	CbGbCtD
Metoprolol—CYP2D6—Nilotinib—hematologic cancer	0.00637	0.0154	CbGbCtD
Metoprolol—CYP2D6—Vinorelbine—hematologic cancer	0.00631	0.0153	CbGbCtD
Metoprolol—CYP2C19—Prednisone—hematologic cancer	0.00607	0.0147	CbGbCtD
Metoprolol—ABCB1—Dasatinib—hematologic cancer	0.00597	0.0144	CbGbCtD
Metoprolol—ABCB1—Mitoxantrone—hematologic cancer	0.0059	0.0143	CbGbCtD
Metoprolol—ABCB1—Betamethasone—hematologic cancer	0.00526	0.0127	CbGbCtD
Metoprolol—ABCB1—Gemcitabine—hematologic cancer	0.00521	0.0126	CbGbCtD
Metoprolol—ABCB1—Prednisolone—hematologic cancer	0.00519	0.0125	CbGbCtD
Metoprolol—ABCB1—Prednisone—hematologic cancer	0.0049	0.0118	CbGbCtD
Metoprolol—ABCB1—Irinotecan—hematologic cancer	0.00464	0.0112	CbGbCtD
Metoprolol—ABCB1—Vinblastine—hematologic cancer	0.00413	0.00998	CbGbCtD
Metoprolol—ABCB1—Vincristine—hematologic cancer	0.00406	0.00981	CbGbCtD
Metoprolol—CYP2D6—Vinblastine—hematologic cancer	0.00389	0.00941	CbGbCtD
Metoprolol—CYP2C19—Dexamethasone—hematologic cancer	0.00379	0.00916	CbGbCtD
Metoprolol—ABCB1—Cisplatin—hematologic cancer	0.00379	0.00915	CbGbCtD
Metoprolol—ABCB1—Etoposide—hematologic cancer	0.00372	0.00899	CbGbCtD
Metoprolol—ABCB1—Dexamethasone—hematologic cancer	0.00306	0.00739	CbGbCtD
Metoprolol—CYP2D6—Dexamethasone—hematologic cancer	0.00288	0.00697	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—hematologic cancer	0.00254	0.00613	CbGbCtD
Metoprolol—ABCB1—Methotrexate—hematologic cancer	0.00246	0.00594	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—hematologic cancer	0.00239	0.00578	CbGbCtD
Metoprolol—Acebutolol—SLC22A1—hematologic cancer	0.000219	0.578	CrCbGaD
Metoprolol—Atenolol—ABCB1—hematologic cancer	6.9e-05	0.182	CrCbGaD
Metoprolol—Acebutolol—ABCB1—hematologic cancer	6.37e-05	0.168	CrCbGaD
Metoprolol—Propranolol—ABCB1—hematologic cancer	2.71e-05	0.0716	CrCbGaD
Metoprolol—Urticaria—Triamcinolone—hematologic cancer	2.09e-05	0.000115	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—hematologic cancer	2.09e-05	0.000115	CcSEcCtD
Metoprolol—Dysgeusia—Methotrexate—hematologic cancer	2.09e-05	0.000115	CcSEcCtD
Metoprolol—Asthenia—Etoposide—hematologic cancer	2.08e-05	0.000115	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—hematologic cancer	2.08e-05	0.000115	CcSEcCtD
Metoprolol—Body temperature increased—Triamcinolone—hematologic cancer	2.08e-05	0.000115	CcSEcCtD
Metoprolol—Oedema—Prednisone—hematologic cancer	2.08e-05	0.000115	CcSEcCtD
Metoprolol—Angiopathy—Epirubicin—hematologic cancer	2.08e-05	0.000115	CcSEcCtD
Metoprolol—Nausea—Irinotecan—hematologic cancer	2.07e-05	0.000114	CcSEcCtD
Metoprolol—Nausea—Mitoxantrone—hematologic cancer	2.07e-05	0.000114	CcSEcCtD
Metoprolol—Immune system disorder—Epirubicin—hematologic cancer	2.07e-05	0.000114	CcSEcCtD
Metoprolol—Mediastinal disorder—Epirubicin—hematologic cancer	2.07e-05	0.000114	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.06e-05	0.000114	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.06e-05	0.000114	CcSEcCtD
Metoprolol—Fatigue—Betamethasone—hematologic cancer	2.06e-05	0.000114	CcSEcCtD
Metoprolol—Fatigue—Dexamethasone—hematologic cancer	2.06e-05	0.000114	CcSEcCtD
Metoprolol—Pruritus—Etoposide—hematologic cancer	2.06e-05	0.000113	CcSEcCtD
Metoprolol—Shock—Prednisone—hematologic cancer	2.05e-05	0.000113	CcSEcCtD
Metoprolol—Arrhythmia—Epirubicin—hematologic cancer	2.05e-05	0.000113	CcSEcCtD
Metoprolol—Pain—Dexamethasone—hematologic cancer	2.04e-05	0.000113	CcSEcCtD
Metoprolol—Pain—Betamethasone—hematologic cancer	2.04e-05	0.000113	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—hematologic cancer	2.04e-05	0.000113	CcSEcCtD
Metoprolol—Nervous system disorder—Prednisone—hematologic cancer	2.04e-05	0.000113	CcSEcCtD
Metoprolol—Tachycardia—Prednisone—hematologic cancer	2.03e-05	0.000112	CcSEcCtD
Metoprolol—Alopecia—Epirubicin—hematologic cancer	2.03e-05	0.000112	CcSEcCtD
Metoprolol—Skin disorder—Prednisone—hematologic cancer	2.02e-05	0.000112	CcSEcCtD
Metoprolol—Nausea—Gemcitabine—hematologic cancer	2.02e-05	0.000111	CcSEcCtD
Metoprolol—Vomiting—Cisplatin—hematologic cancer	2.02e-05	0.000111	CcSEcCtD
Metoprolol—Hyperhidrosis—Prednisone—hematologic cancer	2.01e-05	0.000111	CcSEcCtD
Metoprolol—Vision blurred—Methotrexate—hematologic cancer	2.01e-05	0.000111	CcSEcCtD
Metoprolol—Mental disorder—Epirubicin—hematologic cancer	2.01e-05	0.000111	CcSEcCtD
Metoprolol—Rash—Cisplatin—hematologic cancer	2e-05	0.00011	CcSEcCtD
Metoprolol—Dermatitis—Cisplatin—hematologic cancer	2e-05	0.00011	CcSEcCtD
Metoprolol—Diarrhoea—Etoposide—hematologic cancer	1.99e-05	0.00011	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—hematologic cancer	1.98e-05	0.000109	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—hematologic cancer	1.98e-05	0.000109	CcSEcCtD
Metoprolol—Feeling abnormal—Dexamethasone—hematologic cancer	1.97e-05	0.000109	CcSEcCtD
Metoprolol—Feeling abnormal—Betamethasone—hematologic cancer	1.97e-05	0.000109	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—hematologic cancer	1.97e-05	0.000109	CcSEcCtD
Metoprolol—Flatulence—Epirubicin—hematologic cancer	1.97e-05	0.000108	CcSEcCtD
Metoprolol—Tension—Epirubicin—hematologic cancer	1.96e-05	0.000108	CcSEcCtD
Metoprolol—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.96e-05	0.000108	CcSEcCtD
Metoprolol—Gastrointestinal pain—Betamethasone—hematologic cancer	1.96e-05	0.000108	CcSEcCtD
Metoprolol—Dysgeusia—Epirubicin—hematologic cancer	1.95e-05	0.000108	CcSEcCtD
Metoprolol—Hypersensitivity—Triamcinolone—hematologic cancer	1.94e-05	0.000107	CcSEcCtD
Metoprolol—Nervousness—Epirubicin—hematologic cancer	1.94e-05	0.000107	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—hematologic cancer	1.92e-05	0.000106	CcSEcCtD
Metoprolol—Dizziness—Etoposide—hematologic cancer	1.92e-05	0.000106	CcSEcCtD
Metoprolol—Muscle spasms—Epirubicin—hematologic cancer	1.92e-05	0.000106	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—hematologic cancer	1.92e-05	0.000106	CcSEcCtD
Metoprolol—Vertigo—Methotrexate—hematologic cancer	1.92e-05	0.000106	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—hematologic cancer	1.91e-05	0.000105	CcSEcCtD
Metoprolol—Leukopenia—Methotrexate—hematologic cancer	1.91e-05	0.000105	CcSEcCtD
Metoprolol—Urticaria—Betamethasone—hematologic cancer	1.9e-05	0.000105	CcSEcCtD
Metoprolol—Urticaria—Dexamethasone—hematologic cancer	1.9e-05	0.000105	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.9e-05	0.000105	CcSEcCtD
Metoprolol—Dizziness—Prednisolone—hematologic cancer	1.9e-05	0.000104	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—hematologic cancer	1.9e-05	0.000104	CcSEcCtD
Metoprolol—Asthenia—Triamcinolone—hematologic cancer	1.89e-05	0.000104	CcSEcCtD
Metoprolol—Body temperature increased—Dexamethasone—hematologic cancer	1.89e-05	0.000104	CcSEcCtD
Metoprolol—Body temperature increased—Betamethasone—hematologic cancer	1.89e-05	0.000104	CcSEcCtD
Metoprolol—Abdominal pain—Betamethasone—hematologic cancer	1.89e-05	0.000104	CcSEcCtD
Metoprolol—Abdominal pain—Dexamethasone—hematologic cancer	1.89e-05	0.000104	CcSEcCtD
Metoprolol—Nausea—Cisplatin—hematologic cancer	1.88e-05	0.000104	CcSEcCtD
Metoprolol—Insomnia—Prednisone—hematologic cancer	1.88e-05	0.000104	CcSEcCtD
Metoprolol—Vision blurred—Epirubicin—hematologic cancer	1.88e-05	0.000104	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—hematologic cancer	1.87e-05	0.000103	CcSEcCtD
Metoprolol—Paraesthesia—Prednisone—hematologic cancer	1.87e-05	0.000103	CcSEcCtD
Metoprolol—Pruritus—Triamcinolone—hematologic cancer	1.86e-05	0.000103	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—hematologic cancer	1.86e-05	0.000102	CcSEcCtD
Metoprolol—Vomiting—Etoposide—hematologic cancer	1.85e-05	0.000102	CcSEcCtD
Metoprolol—Dyspepsia—Prednisone—hematologic cancer	1.83e-05	0.000101	CcSEcCtD
Metoprolol—Rash—Etoposide—hematologic cancer	1.83e-05	0.000101	CcSEcCtD
Metoprolol—Dermatitis—Etoposide—hematologic cancer	1.83e-05	0.000101	CcSEcCtD
Metoprolol—Headache—Etoposide—hematologic cancer	1.82e-05	0.0001	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—hematologic cancer	1.82e-05	0.0001	CcSEcCtD
Metoprolol—Arthralgia—Methotrexate—hematologic cancer	1.82e-05	0.0001	CcSEcCtD
Metoprolol—Chest pain—Methotrexate—hematologic cancer	1.82e-05	0.0001	CcSEcCtD
Metoprolol—Tension—Doxorubicin—hematologic cancer	1.81e-05	9.99e-05	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—hematologic cancer	1.81e-05	9.97e-05	CcSEcCtD
Metoprolol—Rash—Prednisolone—hematologic cancer	1.81e-05	9.96e-05	CcSEcCtD
Metoprolol—Dermatitis—Prednisolone—hematologic cancer	1.81e-05	9.95e-05	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.8e-05	9.94e-05	CcSEcCtD
Metoprolol—Fatigue—Prednisone—hematologic cancer	1.8e-05	9.9e-05	CcSEcCtD
Metoprolol—Headache—Prednisolone—hematologic cancer	1.8e-05	9.9e-05	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—hematologic cancer	1.79e-05	9.89e-05	CcSEcCtD
Metoprolol—Vertigo—Epirubicin—hematologic cancer	1.79e-05	9.89e-05	CcSEcCtD
Metoprolol—Syncope—Epirubicin—hematologic cancer	1.79e-05	9.87e-05	CcSEcCtD
Metoprolol—Leukopenia—Epirubicin—hematologic cancer	1.79e-05	9.85e-05	CcSEcCtD
Metoprolol—Constipation—Prednisone—hematologic cancer	1.78e-05	9.82e-05	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—hematologic cancer	1.78e-05	9.79e-05	CcSEcCtD
Metoprolol—Palpitations—Epirubicin—hematologic cancer	1.76e-05	9.72e-05	CcSEcCtD
Metoprolol—Confusional state—Methotrexate—hematologic cancer	1.75e-05	9.68e-05	CcSEcCtD
Metoprolol—Loss of consciousness—Epirubicin—hematologic cancer	1.75e-05	9.67e-05	CcSEcCtD
Metoprolol—Dizziness—Triamcinolone—hematologic cancer	1.74e-05	9.61e-05	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—hematologic cancer	1.74e-05	9.6e-05	CcSEcCtD
Metoprolol—Nausea—Etoposide—hematologic cancer	1.73e-05	9.52e-05	CcSEcCtD
Metoprolol—Hypertension—Epirubicin—hematologic cancer	1.72e-05	9.5e-05	CcSEcCtD
Metoprolol—Feeling abnormal—Prednisone—hematologic cancer	1.72e-05	9.46e-05	CcSEcCtD
Metoprolol—Asthenia—Betamethasone—hematologic cancer	1.72e-05	9.46e-05	CcSEcCtD
Metoprolol—Asthenia—Dexamethasone—hematologic cancer	1.72e-05	9.46e-05	CcSEcCtD
Metoprolol—Nervous system disorder—Methotrexate—hematologic cancer	1.71e-05	9.41e-05	CcSEcCtD
Metoprolol—Thrombocytopenia—Methotrexate—hematologic cancer	1.7e-05	9.4e-05	CcSEcCtD
Metoprolol—Gastrointestinal pain—Prednisone—hematologic cancer	1.7e-05	9.39e-05	CcSEcCtD
Metoprolol—Nausea—Prednisolone—hematologic cancer	1.7e-05	9.39e-05	CcSEcCtD
Metoprolol—Arthralgia—Epirubicin—hematologic cancer	1.7e-05	9.37e-05	CcSEcCtD
Metoprolol—Chest pain—Epirubicin—hematologic cancer	1.7e-05	9.37e-05	CcSEcCtD
Metoprolol—Anxiety—Epirubicin—hematologic cancer	1.69e-05	9.34e-05	CcSEcCtD
Metoprolol—Pruritus—Dexamethasone—hematologic cancer	1.69e-05	9.33e-05	CcSEcCtD
Metoprolol—Pruritus—Betamethasone—hematologic cancer	1.69e-05	9.33e-05	CcSEcCtD
Metoprolol—Skin disorder—Methotrexate—hematologic cancer	1.69e-05	9.32e-05	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.69e-05	9.3e-05	CcSEcCtD
Metoprolol—Hyperhidrosis—Methotrexate—hematologic cancer	1.68e-05	9.28e-05	CcSEcCtD
Metoprolol—Vomiting—Triamcinolone—hematologic cancer	1.68e-05	9.24e-05	CcSEcCtD
Metoprolol—Rash—Triamcinolone—hematologic cancer	1.66e-05	9.16e-05	CcSEcCtD
Metoprolol—Dry mouth—Epirubicin—hematologic cancer	1.66e-05	9.16e-05	CcSEcCtD
Metoprolol—Dermatitis—Triamcinolone—hematologic cancer	1.66e-05	9.15e-05	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—hematologic cancer	1.66e-05	9.15e-05	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—hematologic cancer	1.66e-05	9.13e-05	CcSEcCtD
Metoprolol—Urticaria—Prednisone—hematologic cancer	1.65e-05	9.12e-05	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—hematologic cancer	1.65e-05	9.11e-05	CcSEcCtD
Metoprolol—Headache—Triamcinolone—hematologic cancer	1.65e-05	9.1e-05	CcSEcCtD
Metoprolol—Body temperature increased—Prednisone—hematologic cancer	1.65e-05	9.08e-05	CcSEcCtD
Metoprolol—Abdominal pain—Prednisone—hematologic cancer	1.65e-05	9.08e-05	CcSEcCtD
Metoprolol—Confusional state—Epirubicin—hematologic cancer	1.64e-05	9.06e-05	CcSEcCtD
Metoprolol—Diarrhoea—Dexamethasone—hematologic cancer	1.64e-05	9.02e-05	CcSEcCtD
Metoprolol—Diarrhoea—Betamethasone—hematologic cancer	1.64e-05	9.02e-05	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—hematologic cancer	1.63e-05	9e-05	CcSEcCtD
Metoprolol—Oedema—Epirubicin—hematologic cancer	1.63e-05	8.98e-05	CcSEcCtD
Metoprolol—Hypotension—Methotrexate—hematologic cancer	1.63e-05	8.97e-05	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—hematologic cancer	1.62e-05	8.95e-05	CcSEcCtD
Metoprolol—Shock—Epirubicin—hematologic cancer	1.6e-05	8.84e-05	CcSEcCtD
Metoprolol—Nervous system disorder—Epirubicin—hematologic cancer	1.6e-05	8.81e-05	CcSEcCtD
Metoprolol—Thrombocytopenia—Epirubicin—hematologic cancer	1.59e-05	8.79e-05	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—hematologic cancer	1.59e-05	8.79e-05	CcSEcCtD
Metoprolol—Tachycardia—Epirubicin—hematologic cancer	1.59e-05	8.77e-05	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.59e-05	8.74e-05	CcSEcCtD
Metoprolol—Skin disorder—Epirubicin—hematologic cancer	1.58e-05	8.72e-05	CcSEcCtD
Metoprolol—Dizziness—Betamethasone—hematologic cancer	1.58e-05	8.72e-05	CcSEcCtD
Metoprolol—Dizziness—Dexamethasone—hematologic cancer	1.58e-05	8.72e-05	CcSEcCtD
Metoprolol—Hyperhidrosis—Epirubicin—hematologic cancer	1.57e-05	8.68e-05	CcSEcCtD
Metoprolol—Insomnia—Methotrexate—hematologic cancer	1.57e-05	8.68e-05	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—hematologic cancer	1.57e-05	8.67e-05	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—hematologic cancer	1.57e-05	8.67e-05	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—hematologic cancer	1.57e-05	8.64e-05	CcSEcCtD
Metoprolol—Nausea—Triamcinolone—hematologic cancer	1.57e-05	8.63e-05	CcSEcCtD
Metoprolol—Paraesthesia—Methotrexate—hematologic cancer	1.56e-05	8.62e-05	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.56e-05	8.61e-05	CcSEcCtD
Metoprolol—Dyspnoea—Methotrexate—hematologic cancer	1.55e-05	8.56e-05	CcSEcCtD
Metoprolol—Somnolence—Methotrexate—hematologic cancer	1.55e-05	8.53e-05	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—hematologic cancer	1.54e-05	8.48e-05	CcSEcCtD
Metoprolol—Hypersensitivity—Prednisone—hematologic cancer	1.53e-05	8.46e-05	CcSEcCtD
Metoprolol—Dyspepsia—Methotrexate—hematologic cancer	1.53e-05	8.45e-05	CcSEcCtD
Metoprolol—Hypotension—Epirubicin—hematologic cancer	1.52e-05	8.39e-05	CcSEcCtD
Metoprolol—Vomiting—Betamethasone—hematologic cancer	1.52e-05	8.38e-05	CcSEcCtD
Metoprolol—Vomiting—Dexamethasone—hematologic cancer	1.52e-05	8.38e-05	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—hematologic cancer	1.52e-05	8.38e-05	CcSEcCtD
Metoprolol—Rash—Dexamethasone—hematologic cancer	1.51e-05	8.31e-05	CcSEcCtD
Metoprolol—Rash—Betamethasone—hematologic cancer	1.51e-05	8.31e-05	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—hematologic cancer	1.51e-05	8.31e-05	CcSEcCtD
Metoprolol—Dermatitis—Dexamethasone—hematologic cancer	1.51e-05	8.31e-05	CcSEcCtD
Metoprolol—Dermatitis—Betamethasone—hematologic cancer	1.51e-05	8.31e-05	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.5e-05	8.29e-05	CcSEcCtD
Metoprolol—Fatigue—Methotrexate—hematologic cancer	1.5e-05	8.27e-05	CcSEcCtD
Metoprolol—Headache—Betamethasone—hematologic cancer	1.5e-05	8.26e-05	CcSEcCtD
Metoprolol—Headache—Dexamethasone—hematologic cancer	1.5e-05	8.26e-05	CcSEcCtD
Metoprolol—Asthenia—Prednisone—hematologic cancer	1.49e-05	8.24e-05	CcSEcCtD
Metoprolol—Pain—Methotrexate—hematologic cancer	1.49e-05	8.21e-05	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.48e-05	8.18e-05	CcSEcCtD
Metoprolol—Shock—Doxorubicin—hematologic cancer	1.48e-05	8.18e-05	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—hematologic cancer	1.48e-05	8.15e-05	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—hematologic cancer	1.48e-05	8.14e-05	CcSEcCtD
Metoprolol—Pruritus—Prednisone—hematologic cancer	1.47e-05	8.12e-05	CcSEcCtD
Metoprolol—Insomnia—Epirubicin—hematologic cancer	1.47e-05	8.12e-05	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—hematologic cancer	1.47e-05	8.11e-05	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—hematologic cancer	1.46e-05	8.07e-05	CcSEcCtD
Metoprolol—Paraesthesia—Epirubicin—hematologic cancer	1.46e-05	8.06e-05	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—hematologic cancer	1.46e-05	8.03e-05	CcSEcCtD
Metoprolol—Dyspnoea—Epirubicin—hematologic cancer	1.45e-05	8.01e-05	CcSEcCtD
Metoprolol—Somnolence—Epirubicin—hematologic cancer	1.45e-05	7.98e-05	CcSEcCtD
Metoprolol—Feeling abnormal—Methotrexate—hematologic cancer	1.43e-05	7.91e-05	CcSEcCtD
Metoprolol—Dyspepsia—Epirubicin—hematologic cancer	1.43e-05	7.91e-05	CcSEcCtD
Metoprolol—Diarrhoea—Prednisone—hematologic cancer	1.42e-05	7.86e-05	CcSEcCtD
Metoprolol—Gastrointestinal pain—Methotrexate—hematologic cancer	1.42e-05	7.85e-05	CcSEcCtD
Metoprolol—Nausea—Betamethasone—hematologic cancer	1.42e-05	7.83e-05	CcSEcCtD
Metoprolol—Nausea—Dexamethasone—hematologic cancer	1.42e-05	7.83e-05	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—hematologic cancer	1.41e-05	7.76e-05	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.41e-05	7.75e-05	CcSEcCtD
Metoprolol—Fatigue—Epirubicin—hematologic cancer	1.4e-05	7.74e-05	CcSEcCtD
Metoprolol—Pain—Epirubicin—hematologic cancer	1.39e-05	7.68e-05	CcSEcCtD
Metoprolol—Constipation—Epirubicin—hematologic cancer	1.39e-05	7.68e-05	CcSEcCtD
Metoprolol—Urticaria—Methotrexate—hematologic cancer	1.38e-05	7.62e-05	CcSEcCtD
Metoprolol—Dizziness—Prednisone—hematologic cancer	1.38e-05	7.59e-05	CcSEcCtD
Metoprolol—Body temperature increased—Methotrexate—hematologic cancer	1.38e-05	7.59e-05	CcSEcCtD
Metoprolol—Abdominal pain—Methotrexate—hematologic cancer	1.38e-05	7.59e-05	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.37e-05	7.57e-05	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—hematologic cancer	1.36e-05	7.52e-05	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—hematologic cancer	1.35e-05	7.46e-05	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—hematologic cancer	1.34e-05	7.41e-05	CcSEcCtD
Metoprolol—Feeling abnormal—Epirubicin—hematologic cancer	1.34e-05	7.4e-05	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—hematologic cancer	1.34e-05	7.39e-05	CcSEcCtD
Metoprolol—Gastrointestinal pain—Epirubicin—hematologic cancer	1.33e-05	7.34e-05	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—hematologic cancer	1.33e-05	7.31e-05	CcSEcCtD
Metoprolol—Vomiting—Prednisone—hematologic cancer	1.32e-05	7.3e-05	CcSEcCtD
Metoprolol—Rash—Prednisone—hematologic cancer	1.31e-05	7.24e-05	CcSEcCtD
Metoprolol—Dermatitis—Prednisone—hematologic cancer	1.31e-05	7.23e-05	CcSEcCtD
Metoprolol—Headache—Prednisone—hematologic cancer	1.3e-05	7.19e-05	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.3e-05	7.17e-05	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—hematologic cancer	1.3e-05	7.16e-05	CcSEcCtD
Metoprolol—Urticaria—Epirubicin—hematologic cancer	1.29e-05	7.13e-05	CcSEcCtD
Metoprolol—Pain—Doxorubicin—hematologic cancer	1.29e-05	7.11e-05	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—hematologic cancer	1.29e-05	7.11e-05	CcSEcCtD
Metoprolol—Abdominal pain—Epirubicin—hematologic cancer	1.29e-05	7.1e-05	CcSEcCtD
Metoprolol—Body temperature increased—Epirubicin—hematologic cancer	1.29e-05	7.1e-05	CcSEcCtD
Metoprolol—Hypersensitivity—Methotrexate—hematologic cancer	1.28e-05	7.07e-05	CcSEcCtD
Metoprolol—Asthenia—Methotrexate—hematologic cancer	1.25e-05	6.89e-05	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—hematologic cancer	1.24e-05	6.85e-05	CcSEcCtD
Metoprolol—Nausea—Prednisone—hematologic cancer	1.24e-05	6.82e-05	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.23e-05	6.8e-05	CcSEcCtD
Metoprolol—Pruritus—Methotrexate—hematologic cancer	1.23e-05	6.79e-05	CcSEcCtD
Metoprolol—Hypersensitivity—Epirubicin—hematologic cancer	1.2e-05	6.62e-05	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—hematologic cancer	1.2e-05	6.6e-05	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—hematologic cancer	1.19e-05	6.57e-05	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—hematologic cancer	1.19e-05	6.57e-05	CcSEcCtD
Metoprolol—Diarrhoea—Methotrexate—hematologic cancer	1.19e-05	6.57e-05	CcSEcCtD
Metoprolol—Asthenia—Epirubicin—hematologic cancer	1.17e-05	6.44e-05	CcSEcCtD
Metoprolol—Pruritus—Epirubicin—hematologic cancer	1.15e-05	6.35e-05	CcSEcCtD
Metoprolol—Dizziness—Methotrexate—hematologic cancer	1.15e-05	6.35e-05	CcSEcCtD
Metoprolol—Diarrhoea—Epirubicin—hematologic cancer	1.11e-05	6.14e-05	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—hematologic cancer	1.11e-05	6.12e-05	CcSEcCtD
Metoprolol—Vomiting—Methotrexate—hematologic cancer	1.11e-05	6.1e-05	CcSEcCtD
Metoprolol—Rash—Methotrexate—hematologic cancer	1.1e-05	6.05e-05	CcSEcCtD
Metoprolol—Dermatitis—Methotrexate—hematologic cancer	1.1e-05	6.05e-05	CcSEcCtD
Metoprolol—Headache—Methotrexate—hematologic cancer	1.09e-05	6.01e-05	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—hematologic cancer	1.08e-05	5.96e-05	CcSEcCtD
Metoprolol—Dizziness—Epirubicin—hematologic cancer	1.08e-05	5.94e-05	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—hematologic cancer	1.07e-05	5.88e-05	CcSEcCtD
Metoprolol—Vomiting—Epirubicin—hematologic cancer	1.04e-05	5.71e-05	CcSEcCtD
Metoprolol—Nausea—Methotrexate—hematologic cancer	1.03e-05	5.7e-05	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—hematologic cancer	1.03e-05	5.69e-05	CcSEcCtD
Metoprolol—Rash—Epirubicin—hematologic cancer	1.03e-05	5.66e-05	CcSEcCtD
Metoprolol—Dermatitis—Epirubicin—hematologic cancer	1.03e-05	5.66e-05	CcSEcCtD
Metoprolol—Headache—Epirubicin—hematologic cancer	1.02e-05	5.63e-05	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—hematologic cancer	9.97e-06	5.5e-05	CcSEcCtD
Metoprolol—Nausea—Epirubicin—hematologic cancer	9.67e-06	5.33e-05	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—hematologic cancer	9.58e-06	5.28e-05	CcSEcCtD
Metoprolol—Rash—Doxorubicin—hematologic cancer	9.5e-06	5.24e-05	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—hematologic cancer	9.49e-06	5.23e-05	CcSEcCtD
Metoprolol—Headache—Doxorubicin—hematologic cancer	9.44e-06	5.21e-05	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—hematologic cancer	8.95e-06	4.94e-05	CcSEcCtD
Metoprolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	5.54e-06	0.000134	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—MTR—hematologic cancer	5.53e-06	0.000133	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ABCG2—hematologic cancer	5.53e-06	0.000133	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NUP214—hematologic cancer	5.51e-06	0.000133	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	5.49e-06	0.000132	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	5.47e-06	0.000132	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	5.45e-06	0.000132	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	5.42e-06	0.000131	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ENO2—hematologic cancer	5.42e-06	0.000131	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—MTR—hematologic cancer	5.39e-06	0.00013	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ABCG2—hematologic cancer	5.39e-06	0.00013	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NUP98—hematologic cancer	5.38e-06	0.00013	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	5.37e-06	0.000129	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	5.36e-06	0.000129	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	5.33e-06	0.000129	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ENO2—hematologic cancer	5.29e-06	0.000128	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	5.29e-06	0.000128	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—MTHFR—hematologic cancer	5.29e-06	0.000128	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTT1—hematologic cancer	5.26e-06	0.000127	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	5.26e-06	0.000127	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	5.24e-06	0.000127	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ADCY7—hematologic cancer	5.23e-06	0.000126	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOA3—hematologic cancer	5.23e-06	0.000126	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	5.21e-06	0.000126	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	5.2e-06	0.000125	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	5.2e-06	0.000125	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NUP214—hematologic cancer	5.19e-06	0.000125	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.18e-06	0.000125	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	5.17e-06	0.000125	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	5.14e-06	0.000124	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SDC1—hematologic cancer	5.14e-06	0.000124	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTT1—hematologic cancer	5.13e-06	0.000124	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	5.12e-06	0.000124	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	5.12e-06	0.000124	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	5.11e-06	0.000123	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	5.08e-06	0.000123	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	5.08e-06	0.000123	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ABCG2—hematologic cancer	5.08e-06	0.000123	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—MTR—hematologic cancer	5.08e-06	0.000123	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	5.06e-06	0.000122	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	5.03e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	5.02e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	5.02e-06	0.000121	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SDC1—hematologic cancer	5.01e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	5.01e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	5.01e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	5e-06	0.000121	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ENO2—hematologic cancer	4.99e-06	0.00012	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	4.98e-06	0.00012	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	4.95e-06	0.000119	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	4.92e-06	0.000119	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.91e-06	0.000118	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	4.91e-06	0.000118	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	4.91e-06	0.000118	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.85e-06	0.000117	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTT1—hematologic cancer	4.84e-06	0.000117	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.8e-06	0.000116	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SDC1—hematologic cancer	4.73e-06	0.000114	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	4.69e-06	0.000113	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	4.65e-06	0.000112	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.63e-06	0.000112	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	4.63e-06	0.000112	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	4.58e-06	0.000111	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	4.55e-06	0.00011	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	4.53e-06	0.000109	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	4.52e-06	0.000109	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.5e-06	0.000108	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CG—hematologic cancer	4.44e-06	0.000107	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	4.42e-06	0.000107	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	4.42e-06	0.000107	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CD44—hematologic cancer	4.37e-06	0.000105	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NQO1—hematologic cancer	4.37e-06	0.000105	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	4.32e-06	0.000104	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.28e-06	0.000103	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NQO1—hematologic cancer	4.26e-06	0.000103	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CD44—hematologic cancer	4.26e-06	0.000103	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	4.25e-06	0.000103	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	4.21e-06	0.000102	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	4.16e-06	0.0001	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYCS—hematologic cancer	4.13e-06	9.97e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	4.13e-06	9.96e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CREBBP—hematologic cancer	4.12e-06	9.94e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	4.12e-06	9.93e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	4.11e-06	9.91e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	4.08e-06	9.84e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	4.04e-06	9.75e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYCS—hematologic cancer	4.03e-06	9.73e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	4.03e-06	9.72e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	4.03e-06	9.72e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NQO1—hematologic cancer	4.02e-06	9.69e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CD44—hematologic cancer	4.02e-06	9.69e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HSP90AA1—hematologic cancer	4.01e-06	9.67e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	3.99e-06	9.63e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	3.99e-06	9.63e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	3.94e-06	9.51e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	3.94e-06	9.51e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	3.91e-06	9.43e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CD—hematologic cancer	3.91e-06	9.42e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	3.9e-06	9.42e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	3.9e-06	9.42e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	3.9e-06	9.42e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	3.9e-06	9.42e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALB—hematologic cancer	3.86e-06	9.3e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	3.83e-06	9.25e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	3.83e-06	9.23e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	3.82e-06	9.21e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	3.82e-06	9.21e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	3.82e-06	9.21e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYCS—hematologic cancer	3.8e-06	9.17e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.78e-06	9.11e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	3.75e-06	9.05e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	3.74e-06	9.02e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	3.72e-06	8.96e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.7e-06	8.92e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3R1—hematologic cancer	3.69e-06	8.9e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	3.67e-06	8.85e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	3.66e-06	8.82e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTP1—hematologic cancer	3.64e-06	8.79e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	3.64e-06	8.77e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	3.63e-06	8.77e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	3.62e-06	8.74e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	3.62e-06	8.73e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	3.59e-06	8.66e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTP1—hematologic cancer	3.56e-06	8.58e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	3.56e-06	8.58e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	3.55e-06	8.55e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	3.54e-06	8.54e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.53e-06	8.51e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	3.45e-06	8.33e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ABCB1—hematologic cancer	3.45e-06	8.32e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	3.43e-06	8.28e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CB—hematologic cancer	3.4e-06	8.21e-05	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.4e-06	8.2e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	3.38e-06	8.15e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	3.36e-06	8.11e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	3.36e-06	8.1e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTP1—hematologic cancer	3.35e-06	8.09e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NCOR1—hematologic cancer	3.35e-06	8.08e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTM1—hematologic cancer	3.35e-06	8.08e-05	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	3.32e-06	8.02e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	3.29e-06	7.93e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	3.29e-06	7.93e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTM1—hematologic cancer	3.27e-06	7.88e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NCOR1—hematologic cancer	3.27e-06	7.88e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	3.24e-06	7.82e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	3.21e-06	7.75e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ABCB1—hematologic cancer	3.17e-06	7.65e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	3.17e-06	7.65e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	3.15e-06	7.6e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	3.09e-06	7.45e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	3.08e-06	7.43e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.08e-06	7.43e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.08e-06	7.43e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	3.07e-06	7.42e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	3.02e-06	7.28e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	3.01e-06	7.26e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	2.99e-06	7.22e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	2.99e-06	7.22e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.96e-06	7.14e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTEN—hematologic cancer	2.94e-06	7.1e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	2.93e-06	7.06e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	2.93e-06	7.06e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—MTHFR—hematologic cancer	2.89e-06	6.97e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	2.86e-06	6.89e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	2.81e-06	6.77e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—EP300—hematologic cancer	2.81e-06	6.77e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	2.79e-06	6.74e-05	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	2.78e-06	6.7e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	2.75e-06	6.64e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	2.75e-06	6.63e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	2.75e-06	6.62e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	2.73e-06	6.59e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.72e-06	6.57e-05	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	2.72e-06	6.55e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	2.69e-06	6.49e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	2.69e-06	6.48e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	2.68e-06	6.46e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	2.67e-06	6.45e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	2.67e-06	6.45e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	2.62e-06	6.32e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	2.61e-06	6.31e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.61e-06	6.29e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	2.59e-06	6.25e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	2.58e-06	6.24e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	2.53e-06	6.11e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	2.53e-06	6.1e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	2.53e-06	6.1e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	2.52e-06	6.08e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.49e-06	6e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	2.47e-06	5.97e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	2.47e-06	5.95e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	2.46e-06	5.95e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.43e-06	5.85e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	2.41e-06	5.82e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	2.4e-06	5.78e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	2.34e-06	5.66e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	2.33e-06	5.63e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	2.31e-06	5.58e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	2.31e-06	5.56e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.31e-06	5.56e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.29e-06	5.52e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	2.28e-06	5.51e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	2.26e-06	5.46e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	2.26e-06	5.44e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CREBBP—hematologic cancer	2.25e-06	5.43e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	2.21e-06	5.33e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.19e-06	5.27e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	2.16e-06	5.21e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALB—hematologic cancer	2.16e-06	5.21e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	2.15e-06	5.18e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	2.14e-06	5.17e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.13e-06	5.15e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.12e-06	5.12e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALB—hematologic cancer	2.11e-06	5.08e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	2.1e-06	5.07e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	2.1e-06	5.06e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—hematologic cancer	2.07e-06	5.01e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.06e-06	4.98e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.01e-06	4.86e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.01e-06	4.85e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	1.98e-06	4.79e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALB—hematologic cancer	1.98e-06	4.79e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	1.94e-06	4.68e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.91e-06	4.6e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.9e-06	4.58e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.86e-06	4.49e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	1.82e-06	4.4e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	1.78e-06	4.3e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	1.76e-06	4.26e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.75e-06	4.23e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	1.73e-06	4.16e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AKT1—hematologic cancer	1.7e-06	4.09e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	1.69e-06	4.07e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	1.65e-06	3.98e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTEN—hematologic cancer	1.65e-06	3.97e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.61e-06	3.9e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTEN—hematologic cancer	1.61e-06	3.88e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.58e-06	3.81e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—EP300—hematologic cancer	1.57e-06	3.79e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—EP300—hematologic cancer	1.53e-06	3.7e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTEN—hematologic cancer	1.51e-06	3.65e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	1.49e-06	3.59e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	1.46e-06	3.52e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—EP300—hematologic cancer	1.44e-06	3.48e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.16e-06	2.8e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.13e-06	2.73e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.07e-06	2.58e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AKT1—hematologic cancer	9.49e-07	2.29e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AKT1—hematologic cancer	9.26e-07	2.23e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AKT1—hematologic cancer	8.73e-07	2.11e-05	CbGpPWpGaD
